Request for Proposals (RFP) Notice: Quantification of Drugs of Abuse and Related Substances in Biological Specimens

Notice Number: NOT-DA-18-063

Key Dates
Release Date: September 06, 2018

Related Announcements

Issued by
National Institute on Drug Abuse (NIDA)


The National Institute on Drug Abuse (NIDA) plans to solicit proposals under full and open competition procedures from qualified organizations having the capability to identify and quantify drugs and their metabolites in biological fluids and tissues such as plasma/serum, urine, sweat, saliva, hair and brain and other tissues. The Contractor must be able to:

(1) analyze experimental samples for drug concentrations in biological fluids and/or tissues;

(2) develop more specific and sensitive methods for existing drugs or compounds and provide analytical validations for such methods; and

(3) develop assays that are not currently available for compounds for which specific and sensitive assays are required by the drug abuse research community.

The research drugs may include cannabinoids, opiates, amphetamines, l-alpha-acetyl-methadol (LAAM), naltrexone, methadone, cocaine, phencyclidine, anabolic steroids, opioid peptides and peptidomimetics, benzodiazepines and other drugs and their metabolites. The concentrations of such drugs and metabolites usually appear in biological materials at ng/g or ng/ml levels and therefore require the use of state of the art chromatography methods for separation and highly sensitive instrumentations for identification and quantification, such as gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), and LC-MS-MS.

This is a follow-on procurement to Contract Number HHSN271701400012C titled “Quantification of Drugs of Abuse and Related Substances in Biological Specimens.” It is estimated that a cost reimbursement, level of effort type contract will result from this procurement which will include a one-year base period and four one-year options to extend performance.


In order to handle substances under the Controlled Substances Act of 1970, it is mandatory that offerors possess a Drug Enforcement Administration (DEA) Registration for Chemical Analysis or Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances.


RFP No. NIHDA201800364 will be available electronically on or about September 17, 2018. You can access the RFP through the FedBizOpps (URL: or through the NIDA website (URL: All information required for the submission of a proposal will be contained in or accessible through the RFP package. Responses to the RFP will be due 45 days from the release date. NIDA anticipates an award on or before February 2019. NIDA will consider proposals submitted by any responsible offeror.

Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons or organizations may identify to the Contracting Officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.

This advertisement does not commit the Government to award a contract.


Please direct all inquiries to:

Megan Nathan
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6677